Table of Contents
1 Industry Outlook
1.1 Industry Overview
1.2 Erectile dysfunction
1.3 Industry Trends
1.4 Patient demographics
1.5 PESTLE Analysis
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Total Addressable Market (TAM)
3.2 Segmented Addressable Market (SAM)
3.3 Related Markets
3.4 Regulatory Bodies & Standards
3.5 Clinical trials and ethical issues at different phases of research
3.6 Government Spending and Initiatives
3.7 Porter 5 (Five) Forces
4 Market Characteristics
4.1 Evolution
4.2 Market Segmentation
4.3 Market Dynamics
4.3.1 Drivers
4.3.1.1 Increase in incidence of chronic disorders affecting erection in men
4.3.1.2 Increase prevalence of ED
4.3.1.3 Rise in elderly population
4.3.1.4 Lowering healthcare costs
4.3.1.5 Access quality healthcare
4.3.2 Restraints
4.3.2.1 Complications with ED drugs
4.3.2.2 Patents expiration and entry of new generics
4.3.2.3 Alternative and Substitutes oral drug therapy
4.3.3 Opportunities
4.3.3.1 Focusing on R&D activities
4.3.3.2 Upcoming pipeline drugs
4.3.3.3 Increase awareness and commercial advertisement for ED
4.3.3.4 Stem cell therapy
4.3.4 DRO - Impact Analysis
5 Trends' Roadmap and Projects
5.1 Market Trends & Impact
5.2 Technology Roadmap
6 Early diagnosis can prevent permanent erectile dysfunction
6.1 Overview
7 Meta-Analysis
7.1 ED treatment options
7.2 Future of ED
8 Buying criteria
9 Regions
9.1.1.1 Overview
9.1.2 North America
9.1.2.1 Market Overview:
9.1.3 Europe
9.1.3.1 Market Overview:
9.1.4 APAC
9.1.4.1 Market Overview:
9.1.5 Rest of the World
9.1.5.1 Market Overview:
10 Competitive Landscape
10.1 Competitor Comparison Analysis
11 Vendor Profiles
11.1 Pfizer
11.1.1 Overview
11.1.2 Business unit
11.1.3 Geographic Presence
11.1.4 Business Focus
11.1.5 SWOT Analysis
11.1.6 Business Strategies
11.2 Eli Lilly & Company Ltd
11.2.1 Overview
11.2.2 Business Focus
11.2.3 SWOT Analysis
11.2.4 Business Strategies
11.3 Bayer AG
11.3.1 Overview
11.3.2 Business Unit
11.3.3 Geographic Presence
11.3.4 Business Focus
11.3.5 SWOT Analysis
11.3.6 Business Strategy
11.4 Apricus Biosciences' Inc.
11.4.1 Overview
11.4.2 Business Unit
11.4.3 Geographic Presence
11.4.4 Business Focus
11.4.5 SWOT Analysis
11.4.6 Business Strategy
11.5 Mylan N.V. (Meda Pharmaceuticals Inc.)
11.5.1 Overview
11.5.2 Business Unit
11.5.3 Geographic Presence
11.5.4 Business Focus
11.5.5 SWOT Analysis
11.5.6 Business Strategy
11.6 VIVUS' Inc
11.6.1 Overview
11.6.2 Business Unit
11.6.3 Geographic Presence
11.6.4 Business Focus
11.6.5 SWOT Analysis
11.6.6 Business Strategy
12 Companies to Watch for
12.1 Aquestive Therapeutics
12.1.1 Overview
12.1.2 Aquestive Therapeutics: Key highlights
12.1.3 Aquestive Therapeutics: Key news
12.1.4 Aquestive Therapeutics: Erectile dysfunction offering
12.2 Astellas Pharma Inc
12.2.1 Overview
12.2.2 Astellas Pharma: Key highlights
12.2.3 Astellas Pharma: Key news
12.2.4 Astellas Pharma: Erectile dysfunction offering
12.3 BIOLAB FARMACEUTICA
12.3.1 Overview
12.3.2 BIOLAB FARMACEUTICA: Key highlights
12.3.3 BIOLAB FARMACEUTICA: Key news
12.3.4 BIOLAB FARMACEUTICA: Erectile dysfunction offering
12.4 Biopharm GmbH
12.4.1 Overview
12.4.2 Biopharm GmbH: Key highlights
12.4.3 Biopharm GmbH: Key news
12.4.4 Biopharm GmbH: Erectile dysfunction offering
12.5 Futura Medical plc
12.5.1 Overview
12.5.2 Futura Medical: Key highlights
12.5.3 Futura Medical: Key news
12.5.4 Futura Medical: Erectile dysfunction offering (pipeline products)
12.6 iX Biopharma Ltd.
12.6.1 Overview
12.6.2 iX Biopharma Ltd.: Key highlights
12.6.3 iX Biopharma Ltd.: Key news
12.6.4 iX Biopharma Ltd.: Erectile dysfunction offering (pipeline products)
12.7 SK Chemicals Co.' Ltd.
12.7.1 Overview
12.7.2 SK Chemicals Co.' Ltd.: Key highlights
12.7.3 SK Chemicals Co.' Ltd: Key news
12.7.4 SK Chemicals Co.' Ltd: Erectile dysfunction offering
13 Other prominent vendors
Annexure
? Acronyms